PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-6.83
Negative P/E while Biotechnology median is -2.56. Seth Klarman would scrutinize path to profitability versus peers.
2398.57
P/S exceeding 1.5x Biotechnology median of 7.77. Jim Chanos would check for potential multiple compression risks.
4.11
P/B exceeding 1.5x Biotechnology median of 1.85. Jim Chanos would check for potential asset write-down risks.
-35.08
Negative FCF while Biotechnology median P/FCF is -12.68. Seth Klarman would investigate cash flow improvement potential.
-35.16
Negative operating cash flow while Biotechnology median P/OCF is -12.95. Seth Klarman would investigate operational improvement potential.
4.11
Fair value ratio exceeding 1.5x Biotechnology median of 1.85. Jim Chanos would check for valuation bubble risks.
-3.66%
Negative earnings while Biotechnology median yield is -5.77%. Seth Klarman would investigate path to profitability.
-2.85%
Negative FCF while Biotechnology median yield is -4.16%. Seth Klarman would investigate cash flow improvement potential.